COMPANY PROFILE

Bridge Medicines

Explore full profile

Accelerating the Path to the Patient

New York City, United StatesFounded 2016Biotech & Life Sciences

Valuation $50–100M Last recorded · 2020

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Bridge Medicines

Bridge Medicines is a biopharmaceutical company focused on advancing breakthrough therapeutics for difficult-to-treat cancers. The company operates in the life sciences sector, leveraging cutting-edge research and development to create novel treatments. Bridge Medicines collaborates with leading academic institutions, such as Cornell University, to license and develop promising drug candidates. The company primarily serves patients with resistant cancers, including triple-negative breast cancer (TNBC), by moving innovative research from preclinical validation to human clinical trials. Its business model involves securing exclusive licenses for promising drug candidates, providing financial, operational, and managerial support to transition these candidates through various stages of drug development. Bridge Medicines generates revenue through partnerships, licensing agreements, and potential future sales of approved therapeutics. The company operates within a highly specialized market, targeting unmet medical needs in oncology and other therapeutic areas.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2016
Headquarters: New York City, United States
Employees: 2
Open positions: None listed
Dealroom signal: 23.0/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
EARLY VC✓Equity / VC	Nov 2020	$10M	$40M	Deerfield · Bay City Capital · Takeda	—
OtherOther financing	Oct 2016	$0	—	Deerfield · Bay City Capital · Takeda	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Bridge Medicines website traffic

Latest recorded traffic for Bridge Medicines is 260 monthly website visits, down 76.4% over the last three months. Bridge Medicines's team grew 0% over the past year.

Latest monthly visits260 3-month web change-76.4% 1-year team growth0%

Monthly website visitsOct 2020–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational	44	$217M	$700M
XBXanadu BioPioneering cystic fibrosis treatment through small molecules and gene editing	Lower Merion Township, United States	Operational
STSolve TherapeuticsTargeted cancer therapies enhancing safety and precision	San Diego, United States	Operational
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
BIBioCaptivaNovel liquid biopsy device for cancer diagnostics	St Andrews, United Kingdom	Operational
PEPerformsApplies patented nanotechnology to enhance solubility and delivery of an endogenous anti‑inflammatory molecule for psoriasis treatment	Modena, Italy	Operational
EBExeVir BioCamelid-derived antibody therapies for infectious diseases	Ghent, Belgium	Operational